EUVIMEDEUVIMED entdecken
MetaanalyseNetzwerk-MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta‐analysis

Takafumi Yanagisawa iD, Tatsushi Kawada iD, Keiichiro Mori iD, Sung Ryul Shim, Hadi Mostafaei iD, Reza Sari Motlagh iD, Fahad Quhal, Ekaterina Laukhtina iD, Markus von Deimling, Alberto Bianchi, Muhammad Majdoub, Maximilian Pallauf iD und 4 weitere

BJU International · 2023

DOI: 10.1111/bju.16106 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift BJU International, 2023. Verfasst von Takafumi Yanagisawa und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy of systemic therapies in patients with worse performance status (PS) treated for high‐risk non‐metastatic prostate cancer (PCa), metastatic hormone‐sensitive PCa (mHSPC), and non‐metastatic/metastatic castration‐resistant PCa (nmCRPC/mCRPC), as there is sparse pooled data showing the effect of PS on oncological outcomes in patients with PCa.

Methods

Three databases were queried in June 2022 for randomised controlled trials (RCTs) analysing patients with PCa treated with systemic therapy (i.e., adding androgen receptor signalling inhibitor [ARSI] or docetaxel [DOC] to androgen‐deprivation therapy [ADT]). We analysed the oncological outcomes of patients with PCa with worse PS, defined as Eastern Cooperative Oncology Group PS ≥ 1, treated with combination therapies and compared these to patients with good PS. The main outcomes of interest were overall survival (OS), metastasis‐free survival (MFS), and progression‐free survival.

Results

Overall, 25 and 18 RCTs were included for systematic review and meta‐analyses/network meta‐analyses, respectively. In all clinical settings, combination systemic therapies significantly improved OS in patients with worse PS as well as in those with good PS, while the MFS benefit from ARSI in the nmCRPC setting was more pronounced in patients with good PS than in those with worse PS ( P = 0.002). Analysis of treatment ranking in patients with mHSPC revealed that triplet therapy had the highest likelihood of improved OS irrespective of PS; specifically, adding darolutamide to DOC + ADT had the highest likelihood of improved OS in patients with worse PS. Analyses were limited by the small proportion of patients with a PS ≥ 1 (19%–28%) and that the number of PS 2 was rarely reported.

Conclusions

Among RCTs, novel systemic therapies seem to benefit the OS of patients with PCa irrespective of PS. Our findings suggest that worse PS should not discourage treatment intensification across all disease stages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantHumansMaleAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsDocetaxelProgression-Free Survival

Stichwörter der Autor:innen

Eastern Cooperative Oncology Groupmetastatic castration-resistant prostate cancermetastatic hormone-sensitive prostate cancernon-metastatic castration-resistant prostate cancerperformance status

Substanzen

Androgen AntagonistsDocetaxel

Autor:innen und Institutionen

  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Department of Biomedical Informatics, College of Medicine, Konyang University, Daejeon, Korea.
  • Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Takafumi Yanagisawa, Tatsushi Kawada, Keiichiro Mori, Hadi Mostafaei, Reza Sari Motlagh, Ekaterina Laukhtina, Maximilian Pallauf, Pawel Rajwa

Zitieren

APA

Yanagisawa, T., Kawada, T., Mori, K., Shim, S. R., Mostafaei, H., Sari Motlagh, R., Quhal, F., Laukhtina, E., von Deimling, M., Bianchi, A., Majdoub, M., Pallauf, M., Pradere, B., Kimura, T., Shariat, S. F., & Rajwa, P. (2023). Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta‐analysis. BJU International. https://doi.org/10.1111/bju.16106

Vancouver

Yanagisawa T, Kawada T, Mori K, Shim SR, Mostafaei H, Sari Motlagh R, et al. Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta‐analysis. BJU International. 2023. doi:10.1111/bju.16106

BibTeX
@article{Yanagisawa2023,
  author = {Yanagisawa, Takafumi and Kawada, Tatsushi and Mori, Keiichiro and Shim, Sung Ryul and Mostafaei, Hadi and Sari Motlagh, Reza and Quhal, Fahad and Laukhtina, Ekaterina and von Deimling, Markus and Bianchi, Alberto and Majdoub, Muhammad and Pallauf, Maximilian and Pradere, Benjamin and Kimura, Takahiro and Shariat, Shahrokh F and Rajwa, Pawel},
  title = {Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta‐analysis},
  journal = {BJU International},
  year = {2023},
  doi = {10.1111/bju.16106}
}
Kostenlos starten →